Please assess the completion status of the following clinical trial:

Trial Title: Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Prerandomization Inclusion Criteria:~* Provide written informed consent before initiation of any study related procedures.~* Be at least 18 years of age~* Be scheduled for Coronary Artery Bypass Grafting (CABG), Off Pump Coronary Artery Bypass (OPCAB), Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery, and/or valve replacement/repair surgery~Prerandomization Exclusion Criteria:~* Women of child-bearing potential (unless they have a negative pregnancy test)~* Recent cerebrovascular accident (within 3 months before randomization)~* Known intolerance to calcium channel blockers~* Known or suspected hypersensitivity to nitroglycerin~* Allergy to soybean oil or egg lecithin (components of the lipid vehicle)~* Pre-existing permanent ventricular pacing~* Any other disease or condition, which, in the judgment of the investigator would place a patient at undue risk by being enrolled in the trial~* Participation in another therapeutic drug or therapeutic device trial within 30 days of starting study~Postrandomization Inclusion Criteria:~* Determined to be hypertensive perioperatively as determined by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clevidipine (Type: EXPERIMENTAL): Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
- nitroglycerin (Type: ACTIVE_COMPARATOR): Nitroglycerin (NTG) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.

Based on this trial design, predict the completion outcome and termination type (if applicable).